Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC).

摘要: Abstract Background Despite the well-established benefits of strategies to reduce low-density lipoprotein cholesterol (LDL-C), many patients fail achieve guideline recommended targets. The objective this study was evaluate impact an enhanced 26-week algorithm-based treatment optimization strategy, involving titration statin monotherapy and/or combination therapy with and ezetimibe, on achievement guideline-based LDL-C targets in at high risk for atherosclerotic disease. Methods Results In national (172-physician) quality enhancement research initiative 2334 Canadian men women (median age, 65 years) vascular who were not guideline-recommended target despite therapy, 36.6% 45.5% achieved P 001). Use ezetimibe associated greater achievement. Conclusions a structured algorithm, based dosages incorporation when required, enabled majority high-risk targets, thereby narrowing care gap that exists dyslipidemia management.